AR091234A1 - Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas - Google Patents
Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlasInfo
- Publication number
- AR091234A1 AR091234A1 ARP130101928A AR091234A1 AR 091234 A1 AR091234 A1 AR 091234A1 AR P130101928 A ARP130101928 A AR P130101928A AR 091234 A1 AR091234 A1 AR 091234A1
- Authority
- AR
- Argentina
- Prior art keywords
- variants
- metabolite
- genotypes
- phenotypes
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una combinación de dos o más sustancias farmacéuticamente activas, de las cuales al menos una es un producto metabólico (metabolito) de la otra (sustancia original), en la que en particular sus dosificaciones se seleccionan de modo tal que la variabilidad relacionada con el genotipo o el fenotipo en la conversión de la sustancia original al metabolito en individuos particulares está compensada. Reivindicación 1: Formulación farmacéutica de combinación en dosis fijas que contiene una sustancia original, cuya acción depende de la cantidad o de la actividad de las variantes de proteína expresadas, las variantes enzimáticas, las variantes del receptor o las variantes del transportador, y al menos un metabolito de la misma. Reivindicación 3: Formulación de acuerdo con cualquiera de las reivindicaciones 1 y 2 que comprende tamoxifeno y endoxifeno. Reivindicación 4: Formulación de acuerdo con la reivindicación 3 que comprende 15 - 25 mg de tamoxifeno y 0,25 - 5,0 mg de endoxifeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170401.9A EP2668945A1 (de) | 2012-06-01 | 2012-06-01 | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091234A1 true AR091234A1 (es) | 2015-01-21 |
Family
ID=48520964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101928 AR091234A1 (es) | 2012-06-01 | 2013-05-31 | Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas |
| ARP200101246A AR118842A2 (es) | 2012-06-01 | 2020-04-30 | Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101246A AR118842A2 (es) | 2012-06-01 | 2020-04-30 | Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10285958B2 (es) |
| EP (2) | EP2668945A1 (es) |
| JP (2) | JP6096289B2 (es) |
| KR (1) | KR102129043B1 (es) |
| CN (2) | CN104507464A (es) |
| AR (2) | AR091234A1 (es) |
| AU (1) | AU2013269793B2 (es) |
| BR (1) | BR112014030059B1 (es) |
| CA (1) | CA2875189C (es) |
| DK (1) | DK2854789T3 (es) |
| ES (1) | ES2744306T3 (es) |
| HK (1) | HK1207296A1 (es) |
| HU (1) | HUE045699T2 (es) |
| IL (1) | IL235988B (es) |
| MX (1) | MX370304B (es) |
| NZ (1) | NZ702849A (es) |
| PL (1) | PL2854789T3 (es) |
| PT (1) | PT2854789T (es) |
| RU (1) | RU2683260C2 (es) |
| SA (1) | SA113340607B1 (es) |
| SG (2) | SG11201407791VA (es) |
| TW (1) | TWI644666B (es) |
| WO (1) | WO2013178565A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1317546C (en) | 1985-07-01 | 1993-05-11 | Werner Meier | Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d |
| US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
| US5580728A (en) | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US6760708B1 (en) | 1999-08-19 | 2004-07-06 | Dell Products L.P. | Method and system for migrating stored data to a build-to-order computing system |
| EP1248832A4 (en) | 2000-01-21 | 2004-07-07 | Variagenics Inc | IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION |
| US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
| WO2005023179A2 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| US7504214B2 (en) * | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
| DE10345836A1 (de) | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen |
| JP4732683B2 (ja) | 2003-12-29 | 2011-07-27 | ユニバーサル・バイオ・リサーチ株式会社 | 標的物質の検出方法 |
| WO2005092314A1 (en) | 2004-03-18 | 2005-10-06 | Istituto Nazionale Per Lo Studio E La Cura Del Tum | 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer |
| US7805282B2 (en) | 2004-03-30 | 2010-09-28 | New York University | Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype |
| DE102004025534A1 (de) | 2004-05-25 | 2005-12-15 | Bayer Technology Services Gmbh | Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung |
| US8024128B2 (en) | 2004-09-07 | 2011-09-20 | Gene Security Network, Inc. | System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data |
| US8147615B2 (en) | 2004-11-05 | 2012-04-03 | Infineon Technologies Ag | Method of fabricating semiconductor cleaners |
| RU2007143087A (ru) | 2005-06-02 | 2009-07-20 | Биовэйл Лэборэториз Интернэшнл С.Р.Л. (Bb) | Композиция с модифицированным высвобождением минимум одной формы венлафаксина |
| US20070122824A1 (en) | 2005-09-09 | 2007-05-31 | Tucker Mark R | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime |
| EP1938231A1 (en) | 2005-09-19 | 2008-07-02 | BG Medicine, Inc. | Correlation analysis of biological systems |
| RU2318508C2 (ru) * | 2005-12-28 | 2008-03-10 | Всеволод Иванович Киселев | Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы |
| FR2896896B1 (fr) | 2006-02-02 | 2009-09-25 | Commissariat Energie Atomique | Procede de classification d'evenements ou d'etats en deux etapes |
| DE102006028232A1 (de) | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
| JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | エンドキシフェンの方法および組成物 |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
| CA2716456A1 (en) | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
| WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
| JP4517312B2 (ja) * | 2008-07-08 | 2010-08-04 | ソニー株式会社 | メモリアクセス制御装置および撮像装置 |
| US20110136913A1 (en) * | 2008-08-19 | 2011-06-09 | Goetz Matthew P | Assessing and treating breast cancer patients |
| WO2010036732A1 (en) | 2008-09-25 | 2010-04-01 | Zeltiq Aesthetics, Inc. | Treatment planning systems and methods for body contouring applications |
| US7873482B2 (en) | 2008-12-16 | 2011-01-18 | Bruno Stefanon | Diagnostic system for selecting nutrition and pharmacological products for animals |
| US20120088247A1 (en) | 2009-02-23 | 2012-04-12 | Indian University Research & Technology Corporatio | Materials and methods for treating patients with taxoxifen |
| WO2011072244A1 (en) * | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
| US9372198B2 (en) | 2010-06-17 | 2016-06-21 | Aradigm Corporation | Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals |
| NZ606903A (en) * | 2010-08-26 | 2015-05-29 | Ipca Lab Ltd | Methods for the treatment or prophylaxis of thrombosis or embolism |
| EP2675813A4 (en) * | 2011-06-27 | 2014-04-30 | Ipca Lab Ltd | ANTI THROMBOSIS CONNECTIONS |
| EP2834366A4 (en) | 2012-04-02 | 2016-04-27 | Berg Llc | QUESTION-BASED ASSAYS AND USES THEREOF |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| US9417221B2 (en) | 2013-08-27 | 2016-08-16 | International Business Machines Corporation | Food steganography |
-
2012
- 2012-06-01 EP EP12170401.9A patent/EP2668945A1/de not_active Withdrawn
-
2013
- 2013-05-27 MX MX2014014596A patent/MX370304B/es active IP Right Grant
- 2013-05-27 US US14/403,823 patent/US10285958B2/en active Active
- 2013-05-27 WO PCT/EP2013/060824 patent/WO2013178565A1/de active Application Filing
- 2013-05-27 AU AU2013269793A patent/AU2013269793B2/en active Active
- 2013-05-27 CN CN201380040850.8A patent/CN104507464A/zh active Pending
- 2013-05-27 PT PT13725157T patent/PT2854789T/pt unknown
- 2013-05-27 BR BR112014030059-3A patent/BR112014030059B1/pt active IP Right Grant
- 2013-05-27 PL PL13725157T patent/PL2854789T3/pl unknown
- 2013-05-27 JP JP2015514441A patent/JP6096289B2/ja active Active
- 2013-05-27 CA CA2875189A patent/CA2875189C/en active Active
- 2013-05-27 ES ES13725157T patent/ES2744306T3/es active Active
- 2013-05-27 SG SG11201407791VA patent/SG11201407791VA/en unknown
- 2013-05-27 SG SG10201610072UA patent/SG10201610072UA/en unknown
- 2013-05-27 NZ NZ702849A patent/NZ702849A/en unknown
- 2013-05-27 RU RU2014154140A patent/RU2683260C2/ru active
- 2013-05-27 KR KR1020147036212A patent/KR102129043B1/ko active IP Right Grant
- 2013-05-27 CN CN201910317702.5A patent/CN110075097A/zh active Pending
- 2013-05-27 DK DK13725157.5T patent/DK2854789T3/da active
- 2013-05-27 HU HUE13725157A patent/HUE045699T2/hu unknown
- 2013-05-27 EP EP13725157.5A patent/EP2854789B1/de active Active
- 2013-05-31 AR ARP130101928 patent/AR091234A1/es unknown
- 2013-05-31 TW TW102119266A patent/TWI644666B/zh active
- 2013-06-01 SA SA113340607A patent/SA113340607B1/ar unknown
-
2014
- 2014-11-30 IL IL235988A patent/IL235988B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107896.3A patent/HK1207296A1/xx unknown
-
2016
- 2016-11-09 JP JP2016219156A patent/JP2017048234A/ja active Pending
-
2017
- 2017-01-31 US US15/420,733 patent/US20170326080A1/en not_active Abandoned
- 2017-06-16 US US15/625,553 patent/US20170326081A1/en not_active Abandoned
-
2020
- 2020-04-30 AR ARP200101246A patent/AR118842A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Madreiter-Sokolowski et al. | Targeting mitochondria to counteract age-related cellular dysfunction | |
| BRPI0512660A (pt) | tablete carregável, e, método para a preparação de um tablete | |
| WO2008146178A3 (en) | A novel tablet dosage form | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| PE20190390A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| UY31747A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion | |
| BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| FR2949062B1 (fr) | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments | |
| CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
| NO20081038L (no) | Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering | |
| BR112014002025A2 (pt) | partículas que compreendem compostos ativos com base em poliacrilato | |
| WO2010127205A3 (en) | Fixed dose drug combination formulations | |
| BR112012028090A2 (pt) | comprimidos de meloxicam de baixa concentração | |
| CO6771406A2 (es) | Una composición combinada | |
| BR112015014095A2 (pt) | entrega transmucosal de acetato de glatirâmero | |
| De Sousa Lages et al. | Therapeutics that can potentially replicate or augment the anti-aging effects of physical exercise | |
| AR091234A1 (es) | Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas | |
| BRPI0700133A (pt) | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação | |
| ES2616882T3 (es) | Composición farmacéutica que comprende un agonista del receptor de adenosina A3 (IB-MECA/CF-101) para el tratamiento de la psoriasis | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| ECSP19024033A (es) | Composiciones de tesofensina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |